BRPI0819916A2 - Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno. - Google Patents

Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.

Info

Publication number: BRPI0819916A2
Authority: BR; Brazil
Prior art keywords: antigen binding; binding protein; antibody; fragment; disease
Prior art date: 2007-12-11

Application number

BRPI0819916-7A

Other languages

English (en)

Inventor

Philippe Marc Louis Alard

Jonathan Henry Ellis

Susannah Karen Ford

Volker Germaschewski

Peter Ernest Soden

Pamela Joan Thomas

Trevor Anthony Kenneth Wattam

Ian Richard Catchpole

Gerald Wayne Gough

Alan Peter Lewis

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-11

Filing date

2008-12-09

Publication date

2015-05-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40547800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819916(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-11 Priority claimed from GB0724185A external-priority patent/GB0724185D0/en

2008-04-04 Priority claimed from GB0806230A external-priority patent/GB0806230D0/en

2008-12-09 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2015-05-19 Publication of BRPI0819916A2 publication Critical patent/BRPI0819916A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Psychiatry (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0819916-7A 2007-12-11 2008-12-09 Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno. BRPI0819916A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0724185A GB0724185D0 (en)	2007-12-11	2007-12-11	Antibodies
GB0806230A GB0806230D0 (en)	2008-04-04	2008-04-04	Antibodies
US4383908P	2008-04-10	2008-04-10
PCT/EP2008/067138 WO2009074583A1 (en)	2007-12-11	2008-12-09	Antigen binding proteins

Publications (1)

Publication Number	Publication Date
BRPI0819916A2 true BRPI0819916A2 (pt)	2015-05-19

Family

ID=40547800

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0819916-7A BRPI0819916A2 (pt)	2007-12-11	2008-12-09	Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.

Country Status (24)

Country	Link
US (2)	US20110014182A1 (pt)
EP (1)	EP2222705B1 (pt)
JP (2)	JP5512537B2 (pt)
KR (2)	KR101657637B1 (pt)
CN (1)	CN101970484B (pt)
AR (1)	AR069610A1 (pt)
AU (1)	AU2008334637B2 (pt)
BR (1)	BRPI0819916A2 (pt)
CA (1)	CA2707859A1 (pt)
CL (1)	CL2008003655A1 (pt)
CO (1)	CO6280540A2 (pt)
CR (1)	CR11561A (pt)
DO (1)	DOP2010000170A (pt)
EA (1)	EA022913B1 (pt)
ES (1)	ES2525704T3 (pt)
IL (1)	IL206188A0 (pt)
MA (1)	MA31999B1 (pt)
MX (1)	MX2010006422A (pt)
NZ (1)	NZ586003A (pt)
PE (1)	PE20091449A1 (pt)
TW (1)	TWI388334B (pt)
UY (1)	UY31520A1 (pt)
WO (1)	WO2009074583A1 (pt)
ZA (1)	ZA201004133B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
EP2586795B1 (en)	2007-10-05	2018-05-16	Genentech, Inc.	Use of anti-amyloid beta antibody in ocular diseases
CA2791278C (en)	2010-02-25	2015-11-24	The Johns Hopkins University	Sustained delivery of therapeutic agents to an eye compartment
AU2011282536B2 (en)	2010-07-30	2015-12-24	Ac Immune S.A.	Safe and functional humanized anti beta-amyloid antibody
AR085302A1 (es)	2011-02-24	2013-09-18	Sanofi Sa	Metodo de produccion de anticuerpos sialilados
CA2832106A1 (en) *	2011-04-07	2012-10-11	Neotope Biosciences Limited	Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
US10112988B2 (en) *	2012-01-09	2018-10-30	Icb International, Inc.	Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) *	2012-01-09	2018-10-30	Icb International, Inc.	Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
CA2862999A1 (en) *	2012-01-11	2013-07-18	Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University	Bispecific antibody fragments for neurological disease proteins and methods of use
WO2015006507A1 (en)	2013-07-09	2015-01-15	Annexon, Inc.	Methods of treatment for alzheimer's disease and huntington's disease
AU2014339900B2 (en) *	2013-10-25	2019-10-24	Dana-Farber Cancer Institute, Inc.	Anti-PD-L1 monoclonal antibodies and fragments thereof
DK3105250T3 (da) *	2014-02-10	2020-09-28	Igm Biosciences Inc	Multispecifikke iga-bindingsmolekyler
ES3013108T3 (en) *	2014-11-05	2025-04-11	Annexon Inc	Humanized anti-complement factor c1q antibodies and uses thereof
EP3340983B1 (en)	2015-08-26	2023-10-04	Achillion Pharmaceuticals, Inc.	Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amide compounds for treatment of immune and inflammatory disorders
CN115260310B (zh)	2015-11-24	2025-02-25	安尼艾克松股份有限公司	抗补体因子c1q的fab片段及其应用
EP3405577B8 (en)	2016-01-20	2023-02-15	396419 B.C. Ltd.	Compositions and methods for inhibiting factor d
CN105542005B (zh) *	2016-02-03	2018-11-09	大连理工大学	一种抗人淀粉样β肽的纳米抗体及其应用
EP3529618B1 (en) *	2016-10-19	2020-12-02	Alexion Pharmaceuticals, Inc.	A method of quantitating unbound c5 in a sample
ES2888904T3 (es) *	2016-10-19	2022-01-10	Alexion Pharma Inc	Un método de cuantificación de C5a sin unir en una muestra
WO2018136827A1 (en)	2017-01-20	2018-07-26	Vitrisa Therapeutics, Inc.	Stem-loop compositions and methods for inhibiting factor d
WO2018160891A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceutical, Inc.	Pharmaceutical compounds for treatment of medical disorders
US20200330592A1 (en) *	2017-10-09	2020-10-22	Keith Black	Compositions and methods of treating alzheimer's and other amyloid related diseases
US11814363B2 (en)	2018-09-06	2023-11-14	Achillion Pharmaceuticals, Inc.	Morphic forms of danicopan
BR112021011727A2 (pt)	2018-12-17	2021-08-31	Achillion Pharmaceuticals, Inc	Dosagem direcionada para o tratamento de distúrbios mediados do complemento
WO2020198062A1 (en)	2019-03-22	2020-10-01	Achillion Pharmaceuticals, Inc.	Pharmaceutical compounds for the treatment of complement mediated disorders
US12496279B2 (en)	2019-04-11	2025-12-16	The Johns Hopkins University	Nanoparticles for drug delivery to brain
US20230126447A1 (en) *	2020-03-10	2023-04-27	Achillion Pharmaceuticals, Inc.	Ocular drug depot for complement-mediated disorders
JP2021141861A (ja) *	2020-03-13	2021-09-24	富士フイルム和光純薬株式会社	抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
CN113929748B (zh) *	2020-07-13	2023-10-20	中国科学技术大学	检测bace1酶活性的试剂盒及用途
WO2023114763A1 (en)	2021-12-13	2023-06-22	Annexon, Inc.	Anti-complement factor c1q antibodies with single binding arms and uses thereof
AU2024231685A1 (en) *	2023-03-03	2025-09-25	Case Western Reserve University	Cell adhesion molecule targeted immunotherapies
CN117131608B (zh) *	2023-10-23	2024-03-15	南京航空航天大学	一种基于最佳环量分布的激励盘方法
CN118258998B (zh) *	2024-05-31	2024-08-09	北京大学人民医院	一种抗原特异性b细胞检测探针及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0683234B2 (en) *	1993-01-25	2007-06-06	Takeda Chemical Industries, Ltd.	Antibody against beta-amyloid or their derivative and use thereof
US6972125B2 (en) *	1999-02-12	2005-12-06	Genetics Institute, Llc	Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AU5286999A (en) *	1999-07-23	2001-02-13	Glaxo Group Limited	Combination of an anti-ep-cam antibody with a chemotherapeutic agent
ES2392247T3 (es)	2002-03-05	2012-12-07	Ramot At Tel-Aviv University Ltd.	Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
EP1633786A4 (en) *	2002-10-09	2007-07-25	Rinat Neuroscience Corp	METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
US7575747B2 (en)	2003-02-10	2009-08-18	Applied Molecular Evolution	Aβ binding molecules
PE20061323A1 (es) *	2005-04-29	2007-02-09	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US20070196367A1 (en) *	2006-02-22	2007-08-23	Valentin Dinu	Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
DK2177536T3 (da) *	2006-03-30	2014-07-14	Glaxo Group Ltd	Antistoffer mod amyloid-beta-peptid
US20090022728A1 (en)	2007-03-09	2009-01-22	Rinat Neuroscience Corporation	Methods of treating ophthalmic diseases

2008
- 2008-12-09 EP EP08860577.9A patent/EP2222705B1/en active Active
- 2008-12-09 US US12/746,837 patent/US20110014182A1/en not_active Abandoned
- 2008-12-09 EA EA201000787A patent/EA022913B1/ru not_active IP Right Cessation
- 2008-12-09 US US12/330,541 patent/US8921523B2/en not_active Expired - Fee Related
- 2008-12-09 AR ARP080105335A patent/AR069610A1/es not_active Application Discontinuation
- 2008-12-09 KR KR1020157022610A patent/KR101657637B1/ko not_active Expired - Fee Related
- 2008-12-09 PE PE2008002026A patent/PE20091449A1/es not_active Application Discontinuation
- 2008-12-09 MX MX2010006422A patent/MX2010006422A/es active IP Right Grant
- 2008-12-09 CL CL2008003655A patent/CL2008003655A1/es unknown
- 2008-12-09 UY UY31520A patent/UY31520A1/es not_active Application Discontinuation
- 2008-12-09 JP JP2010537424A patent/JP5512537B2/ja not_active Expired - Fee Related
- 2008-12-09 CN CN200880126884.8A patent/CN101970484B/zh not_active Expired - Fee Related
- 2008-12-09 NZ NZ586003A patent/NZ586003A/xx not_active IP Right Cessation
- 2008-12-09 AU AU2008334637A patent/AU2008334637B2/en not_active Ceased
- 2008-12-09 CA CA2707859A patent/CA2707859A1/en not_active Abandoned
- 2008-12-09 BR BRPI0819916-7A patent/BRPI0819916A2/pt not_active IP Right Cessation
- 2008-12-09 ES ES08860577.9T patent/ES2525704T3/es active Active
- 2008-12-09 WO PCT/EP2008/067138 patent/WO2009074583A1/en not_active Ceased
- 2008-12-09 KR KR1020107015248A patent/KR101629365B1/ko not_active Expired - Fee Related
- 2008-12-09 TW TW097147856A patent/TWI388334B/zh not_active IP Right Cessation
2010
- 2010-06-06 IL IL206188A patent/IL206188A0/en unknown
- 2010-06-08 CO CO10068844A patent/CO6280540A2/es not_active Application Discontinuation
- 2010-06-09 ZA ZA2010/04133A patent/ZA201004133B/en unknown
- 2010-06-09 DO DO2010000170A patent/DOP2010000170A/es unknown
- 2010-07-05 MA MA32987A patent/MA31999B1/fr unknown
- 2010-07-09 CR CR11561A patent/CR11561A/es not_active Application Discontinuation
2014
- 2014-03-26 JP JP2014062826A patent/JP2014177462A/ja active Pending

Also Published As

Publication number	Publication date
EP2222705B1 (en)	2014-10-22
EA022913B1 (ru)	2016-03-31
US20090162358A1 (en)	2009-06-25
TW200932267A (en)	2009-08-01
KR20100099277A (ko)	2010-09-10
KR101629365B1 (ko)	2016-06-14
CR11561A (es)	2010-09-23
CA2707859A1 (en)	2009-06-18
CN101970484B (zh)	2014-10-01
JP2014177462A (ja)	2014-09-25
NZ586003A (en)	2012-08-31
ZA201004133B (en)	2011-11-30
PE20091449A1 (es)	2009-10-07
KR20150100964A (ko)	2015-09-02
CO6280540A2 (es)	2011-05-20
ES2525704T3 (es)	2014-12-29
US8921523B2 (en)	2014-12-30
AU2008334637B2 (en)	2014-08-07
TWI388334B (zh)	2013-03-11
EP2222705A1 (en)	2010-09-01
JP5512537B2 (ja)	2014-06-04
AR069610A1 (es)	2010-02-03
EA201000787A1 (ru)	2010-12-30
AU2008334637A1 (en)	2009-06-18
MX2010006422A (es)	2010-06-25
DOP2010000170A (es)	2010-08-15
MA31999B1 (fr)	2011-01-03
UY31520A1 (es)	2009-08-03
IL206188A0 (en)	2010-12-30
KR101657637B1 (ko)	2016-09-19
US20110014182A1 (en)	2011-01-20
WO2009074583A1 (en)	2009-06-18
JP2011506387A (ja)	2011-03-03
CN101970484A (zh)	2011-02-09
CL2008003655A1 (es)	2010-04-16

Similar Documents

Publication	Publication Date	Title
BRPI1008145A2 (pt)	2016-03-15	proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
IL193986A (en)	2015-08-31	Isolated or part of an antibody selectively associated with human antigen 4t 5, antibody / drug delivery agent, use of this agent for drug preparation and host cell expressing isolated nucleic acid encoded for a heavy and light 5t4 antibody chain
BRPI1010109A2 (pt)	2016-03-15	proteína de ligação ao antígeno tetravalente e biespecífica, método para a preparação de uma proteína de ligação ao antígeno tetravalente e biespecífica, célula hospedeira, composição farmacêutica, uso da proteína de ligação ao antígeno tetravalente biespecífica e método para o tratamento de um paciente que necessita de terapia
BRPI0821168A2 (pt)	2015-10-27	anticorpo, hibridoma, e, métodos para tratar doenças em um paciente e para tratar um paciente de transplante
BR112014002618A2 (pt)	2018-01-23	anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmaceutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de cãncer
BR112013028779A2 (pt)	2017-08-01	proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, método para tratar um paciente humano afligido com um distúrbio ou doença inflamatórios, e, uso de uma composição
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI1016061A2 (pt)	2016-09-13	"proteína de ligação de antígeno, célula hospedeira transfectada ou transformada recombinante, composição farmacêutica, método de tratamento de um paciente humano, uso de uma proteína de ligação de antígeno, método para a redução da agregação de um domínio variável simples de imunoglobulina, vk dab humano derivado de uma estrutura da linha germinativa, e, domínio variável simples de imunoglobulina."
BR112012003809A2 (pt)	2019-09-24	anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BRPI0818620A2 (pt)	2019-09-24	proteína de ligação de antígeno, célula hospedeira recombinante transfomada ou transfectada, composição farmacêutica, método para tratar um paciente humano afligido com inflamação mediada pelo sistema imune, e, uso de uma proteína de ligação de antígeno
BRPI0822162A2 (pt)	2015-06-16	Método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
BRPI0916945A2 (pt)	2015-11-24	métodos para tratar uma doença auto-imune ou distúrbio inflamatório em um indivíduo humano, para tratar esclerose múltipla em um indivíduo, e para identificar anticorpos, anticorpo humano, humanizado ou quimérico isolado ou um fragmento de ligação de antígeno do mesmo, e, proteína de ligação isolada.
BRPI0905761A2 (pt)	2015-07-14	Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
BRPI0811193A2 (pt)	2014-11-11	Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
BRPI1013177A2 (pt)	2016-04-12	construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
BRPI0816097A2 (pt)	2016-11-01	composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0818437A2 (pt)	2015-05-12	Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
UA116194C2 (uk)	2018-02-26	Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
BRPI0813311A2 (pt)	2014-12-23	Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BR112014002614A2 (pt)	2018-02-20	anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmacêutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de câncer
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
WO2008134724A3 (en)	2009-02-12	Methods for administering anti-il-5 antibodies
BRPI0911203A2 (pt)	2016-07-05	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI0907735A2 (pt)	2017-06-13	anticorpo, ácido nucleico isolado, célula hospedeira, camundongo transgênico, hibridoma, composição farmacêutica, método para tratar uma condição ou uma doença associada a um distúrbio imune, cristal, proteína de fusão, e, método para preparar o anticorpo
WO2008065378A3 (en)	2008-07-24	Binding members for interleukin-6

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-23	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2019-02-12	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.